Investor Recommends Celera Spin Out Merck Royalty Asset | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – An investment fund has filed a document with the US Securities and Exchange Commission recommending that Celera spin out, segregate, or distribute its royalty asset that is associated with a Merck drug candidate currently in Phase III studies.

Biotechnology Value Fund filed the Schedule 13D two days ago. The fund and its affiliates own nearly 10 percent of Celera's 81.9 million shares outstanding, as of its last 10-Q, which was filed with the SEC on Nov. 9, 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.